Similarly, inosine monophosphate dehydrogenase 2 (IMPDH2), a key enzyme in purine biosynthesis, is upregulated in cancers, promoting pro-tumorigenic phenotypes and chemotherapy resistance in glioblastoma, colorectal cancer, and triple-negative breast cancer [77–80]. This evidence concerns the gene IMPDH2 and triple-negative breast carcinoma.